Loading
A phase 2 trial of Telisotuzumab vedotin in non-small-cell lung cancer and small-cell lung cancer, run by AbbVie, now recruiting.
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06568939 by AbbVie, with 150 participants planned, started 2025-01-20 and due to reach its primary completion in 2028-02. Interventions recorded: Telisotuzumab Vedotin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.